Surrogate molecular markers for IGHV mutational status in chronic lymphocytic leukemia for predicting time to first treatment

Leukemia Research

Volumn 39, Issue 8, 2015, Pages 840-845

  Morabito, Fortunato ^a,b   Cutrona, Giovanna ^c   Mosca, Laura ^d   D'Anca, Marianna ^d   Matis, Serena ^c   Gentile, Massimo ^a   Vigna, Ernesto ^a   Colombo, Monica ^c   Recchia, Anna Grazia ^b   Bossio, Sabrina ^b   De Stefano, Laura ^b   Maura, Francesco ^e   Manzoni, Martina ^e   Ilariucci, Fiorella ^f   Consoli, Ugo ^g   Vincelli, Iolanda ^h   Musolino, Caterina ⁱ   Cortelezzi, Agostino ^d,e   Molica, Stefano ^j   Ferrarini, Manlio ^c   Neri, Antonino ^d,e   more..

^a Hematology Unit   (Italy)

^b Biotecnology Research Unit   (Italy)

^c UNIVERSITY OF GENOA   (Italy)

^d UNIVERSITY OF MILAN   (Italy)

^e FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

^f Hospital S Maria Nuova   (Italy)

^g Garibaldi Nesima Hospital   (Italy)

^h Hematology Unit   (Italy)

ⁱ UNIVERSITY OF MESSINA   (Italy)

^j Hematology Unit   (Italy)

more..

Author keywords

Chronic lymphocytic leukemia; CRY1; Flow cytometry; Gene expression profiling; IGHV; MBOAT1; Prognostic markers; Progression free survival; SNORA70F; ZAP 70

Indexed keywords

CD19 ANTIGEN; CD5 ANTIGEN; CRYPTOCHROME 1; LIPOPROTEIN LIPASE; MOLECULAR MARKER; RECEPTOR INTERACTING PROTEIN 140; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 3; IMMUNOGLOBULIN VARIABLE REGION; PROTEIN KINASE ZAP 70; TRANSCRIPTOME; TUMOR MARKER; ZAP70 PROTEIN, HUMAN;

ARTICLE; B LYMPHOCYTE; CANCER GROWTH; CANCER PROGNOSIS; CHRONIC LYMPHATIC LEUKEMIA; CONTROLLED STUDY; CRY1 GENE; DISEASE MARKER; DOWN REGULATION; GENE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENE MUTATION; HUMAN; IMMUNOGLOBULIN HEAVY CHAIN GENE; LPL GENE; MAJOR CLINICAL STUDY; MBOAT1 GENE; NRIP1 GENE; PREDICTIVE VALUE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK REDUCTION; SEPT10 GENE; SNORA70F GENE; TGFBR3 GENE; TIME TO FIRST TREATMENT; TIME TO TREATMENT; UPREGULATION; ZNF667 GENE; CLINICAL TRIAL; DISEASE COURSE; FOLLOW UP; GENETICS; IMMUNOGLOBULIN VARIABLE REGION; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MUTATION; PROGNOSIS;

DISEASE PROGRESSION; FOLLOW-UP STUDIES; GENE EXPRESSION PROFILING; GENES, IMMUNOGLOBULIN HEAVY CHAIN; HUMANS; IMMUNOGLOBULIN VARIABLE REGION; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MUTATION; PREDICTIVE VALUE OF TESTS; PROGNOSIS; TIME-TO-TREATMENT; TRANSCRIPTOME; TUMOR MARKERS, BIOLOGICAL; ZAP-70 PROTEIN-TYROSINE KINASE;

EID: 84937525262     PISSN: 01452126     EISSN: 18735835     Source Type: Journal    
DOI: 10.1016/j.leukres.2015.05.005     Document Type: Article

References (21)

1. Gentile M., Cutrona G., Mosca L., Matis S., Fabris S., Lionetti M., et al. Prospective validation of a risk score based on biological markers for predicting progression free survival in Binet stage A chronic lymphocytic leukemia patients: results of the multicenter O-CLL1-GISL study. Am J Hematol 2014, 89(7):743-750. 10.1002/ajh.23729.
2. Gentile M., Mauro F.R., Rossi D., Vincelli I., Tripepi G., Recchia A.G., et al. Italian external and multicentric validation of the MD Anderson Cancer Center nomogram and prognostic index for chronic lymphocytic leukaemia patients: analysis of 1502 cases. Br J Haematol 2014, 167(2):224-232. 10.1111/bjh.13032.
3. Damle R.N., Wasil T., Fais F., Ghiotto F., Valetto A., Allen S.L., et al. gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood 1999, 94(6):1840-1847.
4. Hamblin T.J., Davis Z., Gardiner A., Oscier D.G., Stevenson F.K. Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood 1999, 94(6):1848-1854.
5. Gentile M., Cutrona G., Fabris S., Pesce E.A., Baldini L., Di Raimondo F., et al. Total body computed tomography scan in the initial work-up of Binet stage A chronic lymphocytic leukemia patients: results of the prospective, multicenter O-CLL1-GISL study. Am J Hematol 2013, 88(7):539-544. 10.1002/ajh.23448.
6. Molica S., Giannarelli D., Gentile M., Cutrona G., Di Renzo N., Di Raimondo F., et al. The utility of two prognostic models for predicting time to first treatment in early chronic lymphocytic leukemia patients: results of a comparative analysis. Leuk Res 2013, 37(8):943-947. 10.1016/j.leukres.2013.02.016.
7. Lionetti M., Fabris S., Cutrona G., Agnelli L., Ciardullo C., Matis S., et al. High-throughput sequencing for the identification of NOTCH1 mutations in early stage chronic lymphocytic leukaemia: biological and clinical implications. Br J Haematol 2014, 165(5):629-639. 10.1111/bjh.12800.
8. Stilgenbauer S., Schnaiter A., Paschka P., Zenz T., Rossi M., Döhner K., et al. Gene mutations and treatment outcome in chronic lymphocytic leukemia: results from the CLL8 trial. Blood 2014, 123(21):3247-3254. 10.1182/blood-2014-01-546150.
9. Morabito F., Mosca L., Cutrona G., Agnelli L., Tuana G., Ferracin M., et al. Clinical monoclonal B lymphocytosis versus Rai 0 chronic lymphocytic leukemia: a comparison of cellular, cytogenetic, molecular, and clinical features. Clin Cancer Res 2013, 19(21):5890-5900. 10.1158/1078-0432.CCR-13-0622.
10. Negrini M., Cutrona G., Bassi C., Fabris S., Zagatti B., Colombo M., et al. microRNAome expression in chronic lymphocytic leukemia: comparison with normal B-cell subsets and correlations with prognostic and clinical parameters. Clin Cancer Res 2014, 20(15):4141-4153. 10.1158/1078-0432.CCR-13-2497.
11. Queirós A.C., Villamor N., Clot G., Martinez-Trillos A., Kulis M., Navarro A., et al. A B-cell epigenetic signature defines three biological subgroups of chronic lymphocytic leukemia with clinical impact. Leukemia 2015, 29(3):598-605. 10.1038/leu.2014.252.
12. Fabris S., Mosca L., Cutrona G., Lionetti M., Agnelli L., Ciceri G., et al. Chromosome 2p gain in monoclonal B-cell lymphocytosis and in early stage chronic lymphocytic leukemia. Am J Hematol 2013, 88(1):24-31. 10.1002/ajh.23340.
13. Rosenwald A., Alizadeh A.A., Widhopf G., Simon R., Davis R.E., Yu X., et al. Relation of gene expression phenotype to immunoglobulin mutation genotype in B cell chronic lymphocytic leukemia. J Exp Med 2001, 194(11):1639-1647.
14. Crespo M., Bosch F., Villamor N., Bellosillo B., Colomer D., Rozman M., et al. ZAP-70 expression as a surrogate for immunoglobulin-variable-region mutations in chronic lymphocytic leukemia. N Engl J Med 2003, 348(18):1764-1775.
15. Morabito F., Cutrona G., Mosca L., Fabris S., Matis S., Gentile M., et al. Prognostic role of ZAP-70 in early stage chronic lymphocytic leukemia: results of the analysis from a prospective multicenter observational study. Br J Haematol 2015, 168(3):455-459. 10.1111/bjh.13117.
16. Cheson B.D., Bennett J.M., Grever M., et al. National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guide-lines for diagnosis and treatment. Blood 1996, 87:4990-4997.
17. Tripepi G., Heinze G., Jager K.J., Stel V.S., Dekker F.W., Zoccali C. Risk prediction models. Nephrol Dial Transplant 2013, 28(8):1975-1980. 10.1093/ndt/gft095.
18. Eisele L., Prinz R., Klein-Hitpass L., Nückel H., Lowinski K., Thomale J., et al. Combined PER2 and CRY1 expression predicts outcome in chronic lymphocytic leukemia. Eur J Haematol 2009, 83(4):320-327. 10.1111/j.1600-0609.2009.01287.x.
19. Hanoun M., Eisele L., Suzuki M., Greally J.M., Hüttmann A., Aydin S., et al. Epigenetic silencing of the circadian clock gene CRY1 is associated with an indolent clinical course in chronic lymphocytic leukemia. PLoS ONE 2012, 7(3):e34347. 10.1371/journal.pone.0034347.
20. Trojani A., Di Camillo B., Tedeschi A., Lodola M., Montesano S., Ricci F., et al. Gene expression profiling identifies ARSD as a new marker of disease progression and the sphingolipid metabolism as a potential novel metabolism in chronic lymphocytic leukemia. Cancer Biomarkers 2011-2012, 11(1):15-28. 10.3233/CBM-2012-0259.
21. Ronchetti D., Mosca L., Cutrona G., Tuana G., Gentile M., Fabris S., et al. Small nucleolar RNAs as new biomarkers in chronic lymphocytic leukemia. BMC Med Genomics 2013, 6:27. 10.1186/1755-8794-6-27.